linjc16/ctgov huggingface dataset:
Cortical Excitability and Role of rTMS in Cannabis Use Disorder

Study Overview
=================
Brief Summary
-----------------
Repetitive transcranial magnetic stimulation (rTMS) and cortical excitability have a role in cannabis use disorder

Official Title
-----------------
Cortical Excitability and Role of rTMS in Cannabis Use Disorder

Conditions
-----------------
Cannabis Use Disorder, Moderate

Intervention / Treatment
-----------------
* Device: rTMS


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18to 50 years of age cannabis use disorder according to DSM 5 definition clear consent to participate in study Exclusion Criteria: cardiac peacemaker metal implant in the head as participate will be applied to magnetic field of TMS current intake of any medication affect cognition (as anti psychotic and anti epileptic) current history of neurological , psychiatric or general medical disease .current or previous drug (other than cannabis )or alcohol abuse or participation in another trial during the past 8 weeks . age younger than 18 and older than 50 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: non cannabis addict<br>30 non cannabis addict will be control group | |
| Active Comparator: cannabis addict<br>30 cannabis addict will undergo rTMS | Device: rTMS<br>* Repetitive transcranial magnetic stimulation (rTMS) will be done for cannabis addict<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Determination of role of rTMS for reducing cannabis craving | Incidenc of cannabis craving after rTMS | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimation of cortical excitability in cannabis addict | Incidence of cannabis craving after cortical excitability | 1 year |
Ductus Venosus Doppler at 16 Weeks in Monochorial Pregnancy

Study Overview
=================
Brief Summary
-----------------
Studies shows that the realization of the Ductus venosus Doppler may improve the screening of the twin-twin transfusion syndrome. In this study, we want to compare the outcome of monochorial pregnancy when this Doppler was performed during the ultrasound at16 weeks, and when it wasn't. In order to do that, we will compile past reports (January 2015/ January 2018) of all monochorial pregnancy handled in the hospital of Montpellier and Kremlin Bicêtre. We will establish if the Doppler was done or not, if the twin-twin transfusion syndrome appears and the neonatal outcome.

Official Title
-----------------
Does the Performance of the Ductus Venosus Doppler at 16 Weeks Allow to Increase the Screening of the Twin-twin Transfusion Syndrome and to Reduce the Neonatal Mortality?

Conditions
-----------------
Twin Pregnancy, Monochorionic, Pregnancy Followed

Intervention / Treatment
-----------------
* Other: Ductus venosus Doppler


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Monochorionic diamniotic twin pregnancies Monochorionicity diagnosed at the first-trimester Follow up and ultrasound realized at the hospital of Montpellier or Kremlin Bicêtre Screening for twin-twin transfusion syndrome achieved Exclusion criteria: Missing ultrasound Unregistered outcome of the pregnancy Eclampsia and pre-eclampsia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ductus venosus Doppler realized<br>Ductus venosus Doppler realized | Other: Ductus venosus Doppler<br>* Ductus venosus Doppler<br>|
| Ductus venosus Doppler unrealized<br>Ductus venosus Doppler unrealized | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of a twin to twin transfusion syndrome | Occurrence of a twin to twin transfusion syndrome during pregnancy | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| neonatal mortality rate | neonatal mortality rate | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ductus venosus Doppler
Use of Amplified Sound Signal to Identify Presence of Carotid and Femoral Stenosis

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to test a new amplified stethoscope(AudioDoc) that can detect the presence of bruit by using an acoustic signal to represent the bruit. This pilot study will address two questions: is there a detectable difference in recorded sound signal of carotid and femoral bruit when compared to sound signals captured when there is no bruit present; is the use of a visual recorded signal more accurate in identifying carotid and femoral bruit when compared to traditional auscultation with a regular stethoscope and ultrasound.

Detailed Description
-----------------
Recorded signals are stored on a laptop computer. The signals later undergo Fourier analysis are then compared to the findings on carotid ultrasoud as to degree of stenosis. Subjects with high grade stenosis in which no bruit was ascultated but in which carotid ultrasound data suggests a bruit may be present are studied for soft /inaudible bruits. When available, data will be correlated to CT/conventional angiographic studies.

Official Title
-----------------
Use of Amplified Sound Signal to Identify Presence of Carotid and Femoral Stenosis

Conditions
-----------------
Carotid Stenosis, Femoral Arterial Stenosis, Carotid Bruit Asymptomatic, Carotid Murmur

Intervention / Treatment
-----------------
* Device: AudioDoc


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 19-90 years having clinical ultrasound evaluation of carotid or femoral artery Exclusion Criteria: under age 19; over age 90 years

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| adults<br>adults audiodoc use to evaluate for carotid or femoral bruit | Device: AudioDoc<br>* AudioDoc will be used to identify the carotid and femoral bruit<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of bruit signal obtained from the amplified stethoscope(AudioDoc) to that found by conventional ultrasonography. |  | subjects will be followed for duration of hospital stay, typically four days. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the frequency spectral differences obtained from the different recording modalities |  | duration of hospital stay, typically four days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
carotid stenosis, femoral artery ischemia, carotid bruit asymptomatic, carotid murmur
Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to develop and implement robust analytical protocols for first-void urine sample preparation and antibody assays to monitor vaccine induced immunity against HPV (Human Papillomavirus).

Detailed Description
-----------------
Participants of the HPV V503-004 study (Phase III Clinical trial vaccinating (young) adult women in Antwerp, EudraCT NUMBER: 2015-005093-38) will be asked if they are willing to provide two additional urine samples at day 1 and month 7 for biomedical research. Furthermore, they will be contacted again at approximately 3.5 years and asked if they are willing to provide an additional urine sample and a serum sample. At 3.5 years, they will also be asked to fill in a brief questionnaire. The collected urine will be used for the development and optimization of robust analytical protocols for sample preparation and antibody assays.

Official Title
-----------------
Study for the Development of Standard Operating Procedures for Anti-HPV Antibody Detection in First-void Urine: the AB-SOP Follow-up Study

Conditions
-----------------
Human Papilloma Virus Infection

Intervention / Treatment
-----------------
* Other: First-void urine collection
* Other: Blood draw


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participant of the HPV V503-004 study at UA/UZA Willing to give informed consent (ICF) to the CEV research team

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: First-void urine collection|Collection of ca. 20 ml of first-void urine with the Colli-PeeTM device (Novosanis) during visit at the Centre for the Evaluation of Vaccination.|
|Other: Blood draw|Blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccination.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of HPV specific IgG (Immunoglobulin G) in FV urine. | To detect HPV specific IgG concentrations (ratio HPV specific IgG/total human IgG), in first-void urine from 63 women to monitor the immune response before and after vaccination with a prophylactic HPV vaccine (Gardasil9). | Within 6 months after study completion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Antibodies, Vaccination, Self-sampling, First-void urine, HPV
Postoperative Hyperthyroidism

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the frequency and the clinical course of postoperative hyperthyroidism following surgery of tertiary hyperparathyroidism (THP) and to determine the diagnostic value of thyroglobulin in this setting.

Official Title
-----------------
Postoperative Hyperthyroidism After Parathyroidectomy

Conditions
-----------------
Hyperthyroidism

Intervention / Treatment
-----------------
* Other: No intervention performed


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with tertiary hyperparathyroidism undergoing surgery for this reason dialysis treatment Exclusion Criteria: patients wish

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| THP<br>THP: patients undergoing parathyroidectomy according to tertiary hyperparathyroidism | Other: No intervention performed<br> <br> |
| Other causes<br>patients with hyperthyroidism not caused by parathyroidectomy | Other: No intervention performed<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hyperthyroidism |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thyroglobulin elevation |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hyperthyroidism, tertiary hyperparathyroidism, palpation thyroiditis, parathyroidectomy, thyroglobulin, rate of postoperative hyperthyroidism
Comparison of the Detection Rates of 50 Gr-100 gr OGTT and 75 gr OGTT That Require Medical Treatment of GDM

Study Overview
=================
Brief Summary
-----------------
Both 50 gr OGTT-100 gr OGTT and 75 gr OGTT are used for detecting gestational diabetes mellitus. Two approaches are approved by obstetricians. With this study, we aim to compare the gestational diabetes mellitus detection rate of these different tests.

Official Title
-----------------
Comparison of the Detection Rates of 50 Gr-100 gr OGTT and 75 gr OGTT That Require Medical Treatment of GDM

Conditions
-----------------
Gestational Diabetes, Glucose Intolerance During Pregnancy

Intervention / Treatment
-----------------
* Diagnostic Test: Oral glucose tolerance test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women Exclusion Criteria: Already diagnosed by diabetes mellitus Multiple pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 50 gr-100 gr OGTT<br>patients are tested firstly by 50 gr OGTT after that if necessary by 100 gr OGTT | Diagnostic Test: Oral glucose tolerance test<br>* Oral glucose tolerance test<br>|
| Active Comparator: 75 gr OGTT<br>patients are tested by 75 gr OGTT | Diagnostic Test: Oral glucose tolerance test<br>* Oral glucose tolerance test<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| the difference of GDM detection rate of 50 gr- 100 gr OGTT and 75 gr OGTT | to determine the ideal diagnostic test | one year |
Synovectomy in Primary Total Knee Arthrplasty

Study Overview
=================
Brief Summary
-----------------
The aim of total knee arthroplasty is to achieve best patient functional outcomes, improve patient pain score and satisfaction. Synovial proliferation is a common finding in arthritic knees. Surgeons can't decide if synovectomy is a crucial step in the operation. Studies didn't prove the clear benefits of synovectomy. We are aiming to perform a randomized clinical trial trying to reach the best evidence in that matter.

Official Title
-----------------
Synovectomy Versus no Synovectomy in Primary Total Knee Arthrplasty : A Randomized Control Trial

Conditions
-----------------
Arthroplasty, Replacement, Knee, Synovectomy

Intervention / Treatment
-----------------
* Other: Synovectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with primary osteoarthritis undergoing primary total knee arthroplasty Exclusion Criteria: Inflammatory arthritis Revision knee arthroplasty
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Synovectomy<br> | Other: Synovectomy<br>* Removal of the synovium during total knee arthroplasty<br>|
| No Intervention: No synovectomy<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional outcome scores. e.g. knee society score (KSS) |  | one year | 
| knee pain e.g. visual analogue score (VAS) score |  | immediate postoperative | 
| Health related quality of life e.g. short form (SF12) scale |  | one year | 
| Revision rate |  | one year | 
| Reoperation rate |  | one year | 
| Range of motion |  | immediate postoperative | 
| Range of motion |  | 6 month | 
| Range of motion |  | One year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative blood loss |  | immediate postoperative | 
| Postoperative hemoglobin level | gram/dl | immediate postoperative | 
| Infection rate |  | in first three month | 
| Wound complications |  | in first 3 months | 
| Number of patients requiring transfusion |  | immediate postoperative |
Single Ascending Dose Study of Intravenous TRV130A in Healthy Adult Males

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the safety, blood levels, and effects of TRV130A on pain perception and sedation in healthy adult males.

Official Title
-----------------
A Multi-Part, Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TRV130A in Healthy Adult Males

Conditions
-----------------
Healthy

Intervention / Treatment
-----------------
* Drug: TRV130A
* Drug: Dextrose in Water


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adult male 19 - 50 years of age Body weight >/= 50 kg Capable of giving written informed consent Exclusion Criteria: Clinically significant disease or conditions that may place the subject at unacceptable risk as a participant in the study, or that may interfere with the safety, tolerability or pharmacodynamic evaluations in the study Laboratory tests positive for HIV, Hepatitis B virus surface antigen, or Hepatitis C virus antibody; elevations of aspartate aminotransferase or alanine aminotransferase; positive drug or alcohol test; positive urine test for cotinine Major surgery within 4 weeks of screening

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TRV130A<br> | Drug: TRV130A<br>* Intravenous infusion of 1 hour duration<br>|
| Placebo Comparator: Dextrose in Water<br> | Drug: Dextrose in Water<br>* Intravenous infusion of 1 hour duration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of subjects with adverse events |  | Baseline to 8 days after dose administration | 
| Area under the plasma concentration versus time curve of TRV130A |  | Baseline to 24 hours after dose administration | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Effect of TRV130A on pain perception using cold pain test |  | Baseline to 3 hours after dose administration | 
| Effect of TRV130A on pupil diameter |  | Baseline to 3 hours after dose administration | 
| Effect of TRV130A on eye movements | Using saccadic eye movement measurement | Baseline to 3 hours after dose administration | 
| Effect of TRV130A on sedation | Sedation evaluated by questionnaire | Baseline to 3 hours after dose administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
safety, tolerability, TRV130A
An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate of the long-term safety and efficacy of KCT-0809 in dry eye patients with Sjögren's syndrome.

Conditions
-----------------
Dry Eye With Sjögren's Syndrome

Intervention / Treatment
-----------------
* Drug: KCT-0809 ophthalmic solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Dry eye patients with Sjögren's syndrome finished KCT1301 study Exclusion Criteria: Patients with poor adherence to medication of study drug in KCT1301 study

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: KCT-0809<br> | Drug: KCT-0809 ophthalmic solution<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidences of adverse events |  | 52 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score of the corneal staining |  | 52 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Dry eye syndromes, Corneal diseases, Conjunctival diseases